Biodesix shares surge 20.30% after-hours after reporting better-than-expected Q4 2025 results, including 41% revenue growth and positive EBITDA.

Biodesix Inc. surged 20.30% in after-hours trading following the release of preliminary fourth-quarter and full-year 2025 results that exceeded guidance. The company reported Q4 revenue of $28.8 million, a 41% year-over-year increase, and full-year revenue of $88.5 million, surpassing its raised guidance of $84–$86 million. Notably, Biodesix achieved positive adjusted EBITDA in Q4, marking a key profitability milestone, while its cash position improved to $19.0 million. The results highlighted strong operating leverage and growth in lung diagnostics test volumes, driven by expanded reimbursement and improved payer dynamics. Canaccord Genuity reiterated a Buy rating with a $20.00 price target, citing the company’s operational execution and sales force reorganization. The positive earnings beat and improved financial metrics, including reduced cash burn concerns, directly fueled the sharp after-hours rally.